Compare HMY & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | LNTH |
|---|---|---|
| Founded | 1950 | 1956 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 4.9B |
| IPO Year | N/A | 2014 |
| Metric | HMY | LNTH |
|---|---|---|
| Price | $14.11 | $74.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.00 | ★ $83.20 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 02-04-2016 | 05-06-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.41 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $40.34 | N/A |
| Revenue Next Year | $22.08 | $13.93 |
| P/E Ratio | ★ $15.60 | $22.42 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $12.57 | $47.27 |
| 52 Week High | $26.04 | $108.86 |
| Indicator | HMY | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 47.04 |
| Support Level | $13.53 | $72.33 |
| Resistance Level | $15.65 | $84.77 |
| Average True Range (ATR) | 0.64 | 2.75 |
| MACD | -0.11 | -0.89 |
| Stochastic Oscillator | 17.58 | 8.36 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.